Medicine and Dentistry
Janus Kinase
100%
Ruxolitinib
50%
Fedratinib
50%
Myeloproliferative Neoplasm
37%
Assay
12%
Therapeutic Procedure
12%
PADGEM Protein
12%
Patient
12%
Blood
12%
Blood Sampling
12%
Secretion (Process)
12%
Cell Adhesion
12%
Leukocyte
12%
Endothelial Cell
12%
Coagulation
12%
Anti-Inflammatory Drug
12%
Graft Versus Host Reaction
12%
Antithrombotic
12%
COVID-19
12%
Absence
12%
Thromboembolism
12%
Upregulation
12%
Vascular Endothelial Cell
12%
Urokinase
12%
Thromboplastin
12%
Von Willebrand Factor
12%
Procoagulant
12%
Acute Disease
12%
Janus Kinase Inhibitor
12%
Immunofluorescence
12%
Biochemistry, Genetics and Molecular Biology
Janus Kinase
100%
Ruxolitinib
50%
Sample
12%
Quantitative Reverse Transcription Polymerase Chain Reaction
12%
Host
12%
Cell Adhesion
12%
Secretion (Process)
12%
Adhesion
12%
Plasminogen Activator
12%
Urokinase
12%
Coagulation
12%
Western Blot
12%
Transcription
12%
Upregulation
12%
Leukocytes
12%
Immunofluorescence
12%
Tissue Factor
12%
STAT1
12%
Von Willebrand Factor
12%
STAT3
12%
Interleukin-6
12%
P-Selectin
12%
Janus Kinase Inhibitor
12%
Pharmacology, Toxicology and Pharmaceutical Science
Janus Kinase
100%
Ruxolitinib
50%
Fedratinib
50%
Myeloproliferative Neoplasm
37%
Anticoagulant Agent
12%
Graft Versus Host Reaction
12%
Thromboembolism
12%
Urokinase
12%
Absence
12%
Thromboplastin
12%
P-Selectin
12%
Von Willebrand Factor
12%
Acute Disease
12%
Procoagulant
12%
Janus Kinase Inhibitor
12%